OA11222A - Quinoline and quinoxaline compounds which inhibit platelet-derived growt factor and/or p561 ck tyrosine kinases - Google Patents

Quinoline and quinoxaline compounds which inhibit platelet-derived growt factor and/or p561 ck tyrosine kinases Download PDF

Info

Publication number
OA11222A
OA11222A OA9900262A OA9900262A OA11222A OA 11222 A OA11222 A OA 11222A OA 9900262 A OA9900262 A OA 9900262A OA 9900262 A OA9900262 A OA 9900262A OA 11222 A OA11222 A OA 11222A
Authority
OA
OAPI
Prior art keywords
compound
amine
optionally substituted
compound according
solvaté
Prior art date
Application number
OA9900262A
Other languages
English (en)
Inventor
Wei He
Michael R Myers
Alfred P Spada
Martin P Maguire
Original Assignee
Rhone Poulenc Rorer Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer Pharma filed Critical Rhone Poulenc Rorer Pharma
Publication of OA11222A publication Critical patent/OA11222A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/42—Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/50—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to ring nitrogen atoms
    • C07D241/52—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/50—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to ring nitrogen atoms
    • C07D241/54—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/06—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing isoquinuclidine ring systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
OA9900262A 1997-05-28 1999-11-29 Quinoline and quinoxaline compounds which inhibit platelet-derived growt factor and/or p561 ck tyrosine kinases OA11222A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86445597A 1997-05-28 1997-05-28
US97261497A 1997-11-18 1997-11-18

Publications (1)

Publication Number Publication Date
OA11222A true OA11222A (en) 2003-07-16

Family

ID=27127839

Family Applications (3)

Application Number Title Priority Date Filing Date
OA9900262A OA11222A (en) 1997-05-28 1999-11-29 Quinoline and quinoxaline compounds which inhibit platelet-derived growt factor and/or p561 ck tyrosine kinases
OA9900260A OA11264A (en) 1997-05-28 1999-11-29 Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p561ck tyrosine kinases
OA9900261A OA11221A (en) 1997-05-28 1999-11-29 Quinoline and quinoxaline compounds which inhibit platelet-derived growt factor and/or p561ck tyrosine kinases

Family Applications After (2)

Application Number Title Priority Date Filing Date
OA9900260A OA11264A (en) 1997-05-28 1999-11-29 Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p561ck tyrosine kinases
OA9900261A OA11221A (en) 1997-05-28 1999-11-29 Quinoline and quinoxaline compounds which inhibit platelet-derived growt factor and/or p561ck tyrosine kinases

Country Status (25)

Country Link
EP (3) EP0991628B1 (ru)
JP (3) JP2002500675A (ru)
KR (2) KR100425638B1 (ru)
CN (3) CN1261353A (ru)
AP (3) AP1362A (ru)
AT (3) ATE493389T1 (ru)
AU (3) AU742739B2 (ru)
BG (3) BG64419B1 (ru)
BR (3) BR9809172A (ru)
CA (3) CA2291774A1 (ru)
CZ (3) CZ296845B6 (ru)
DE (3) DE69842151D1 (ru)
DK (1) DK0991628T3 (ru)
EA (4) EA004103B1 (ru)
ES (1) ES2235331T3 (ru)
HU (2) HUP0002084A3 (ru)
IL (3) IL133008A0 (ru)
NO (3) NO323721B1 (ru)
OA (3) OA11222A (ru)
PL (3) PL194670B1 (ru)
PT (1) PT991628E (ru)
SI (1) SI0991628T1 (ru)
SK (4) SK158199A3 (ru)
UA (1) UA57790C2 (ru)
WO (3) WO1998054158A1 (ru)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6159978A (en) * 1997-05-28 2000-12-12 Aventis Pharmaceuticals Product, Inc. Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
US6245760B1 (en) 1997-05-28 2001-06-12 Aventis Pharmaceuticals Products, Inc Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
KR100425638B1 (ko) * 1997-05-28 2004-04-03 아벤티스 파마슈티칼스 인크. 혈소판-유도된 성장 인자 및/또는 Ｐ５６ｌｃｋ 티로신키나제를 억제하는 퀴놀린 및 퀴녹살린 화합물
US6180632B1 (en) * 1997-05-28 2001-01-30 Aventis Pharmaceuticals Products Inc. Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
GB9904103D0 (en) 1999-02-24 1999-04-14 Zeneca Ltd Quinoline derivatives
US6506769B2 (en) 1999-10-06 2003-01-14 Boehringer Ingelheim Pharmaceuticals, Inc. Heterocyclic compounds useful as inhibitors of tyrosine kinases
US7101869B2 (en) 1999-11-30 2006-09-05 Pfizer Inc. 2,4-diaminopyrimidine compounds useful as immunosuppressants
EP1309596B1 (en) 2000-08-11 2008-02-06 Boehringer Ingelheim Pharmaceuticals Inc. Heterocyclic compounds useful as inhibitors of tyrosine kinases
NZ535239A (en) 2002-03-27 2008-03-28 Glaxo Group Ltd Quinoline derivatives and their use as 5-HT6 ligands
DE10237423A1 (de) * 2002-08-16 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von LCK-Inhibitoren für die Behandlung von immunologischen Erkrankungen
US20050043233A1 (en) * 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
PL1558582T3 (pl) 2003-07-22 2006-05-31 Arena Pharm Inc Diarylowe i aryloheteroarylowe pochodne mocznika jako modulatory receptora serotoninowego 5-HT2A użyteczne w profilaktyce i w leczeniu zaburzeń związanych z tym receptorem
EP1711467A2 (en) 2004-01-16 2006-10-18 Wyeth Quinoline intermediates of receptor tyrosine kinase inhibitors and the synthesis thereof
WO2008141065A1 (en) 2007-05-10 2008-11-20 Smithkline Beecham Corporation Quinoxaline derivatives as p13 kinase inhibitors
US9084742B2 (en) 2007-12-12 2015-07-21 Axovant Sciences Ltd. Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-Quinoline
WO2009123714A2 (en) 2008-04-02 2009-10-08 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
US9126946B2 (en) 2008-10-28 2015-09-08 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
EP2241557A1 (de) 2009-04-02 2010-10-20 Æterna Zentaris GmbH Chinoxalin-Derivate und deren Anwendung zur Behandlung gutartiger und bösartiger Tumorerkrankungen
JP5728683B2 (ja) 2009-09-04 2015-06-03 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ チロシンスレオニンキナーゼ阻害剤としての置換アミノキノキサリン
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
CN101823998B (zh) * 2010-05-05 2015-03-25 江苏利田科技股份有限公司 一种反应器耦合模拟移动床乙氧基喹啉清洁生产工艺
ES2553771T3 (es) 2010-10-08 2015-12-11 Nivalis Therapeutics, Inc. Nuevos compuestos de quinolina sustituidos como inhibidores de la S-nitrosoglutatión reductasa
GB201020179D0 (en) 2010-11-29 2011-01-12 Astex Therapeutics Ltd New compounds
AU2011343518B2 (en) 2010-12-16 2016-11-10 Nivalis Therapeutics, Inc. Novel substituted bicyclic aromatic compounds as S-nitrosoglutathione reductase inhibitors
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
GB201118654D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118675D0 (en) 2011-10-28 2011-12-14 Astex Therapeutics Ltd New compounds
GB201118652D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118656D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
CN104284896B (zh) 2012-03-14 2016-06-01 拜耳知识产权有限责任公司 取代的咪唑并哒嗪
CN106977495B (zh) 2012-04-24 2020-08-04 沃泰克斯药物股份有限公司 Dna-pk抑制剂
GB201209613D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
GB201209609D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
HRP20170430T1 (hr) 2012-06-13 2017-06-16 Incyte Holdings Corporation Supstituirani triciklični spojevi kao inhibitori fgfr
WO2014026125A1 (en) 2012-08-10 2014-02-13 Incyte Corporation Pyrazine derivatives as fgfr inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
HRP20211855T1 (hr) 2013-03-12 2022-03-04 Vertex Pharmaceuticals Incorporated Inhibitori dnk-pk
PL2986610T4 (pl) 2013-04-19 2019-06-28 Incyte Holdings Corporation Bicykliczne heterocykle jako inhibitory FGFR
GB201307577D0 (en) 2013-04-26 2013-06-12 Astex Therapeutics Ltd New compounds
HK1221955A1 (zh) 2013-06-11 2017-06-16 Bayer Pharma Aktiengesellschaft 取代的三唑并吡啶的前体药物衍生物
PE20161022A1 (es) 2013-10-17 2016-11-12 Vertex Pharma Cocristales de (s)-n-metil-8-(1-((2'-metil-[4,5´-bipirimidin]-6-il)amino)propan-2-il)quinolina-4-carboxamida y sus derivados deuterados como inhibidores de proteinas quinasa dependientes de adn
JO3512B1 (ar) 2014-03-26 2020-07-05 Astex Therapeutics Ltd مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
WO2015144804A1 (en) 2014-03-26 2015-10-01 Astex Therapeutics Ltd Combinations
US10736900B2 (en) 2014-03-26 2020-08-11 Astex Therapeutics Ltd Combinations of an FGFR inhibitor and an IGF1R inhibitor
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
TWI834020B (zh) 2015-02-10 2024-03-01 英商阿斯迪克治療公司 新穎組成物
MY197720A (en) 2015-02-20 2023-07-10 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
WO2016134294A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
HK1245660A1 (zh) 2015-06-12 2018-08-31 Axovant Sciences Gmbh 有用於预防和治疗rem睡眠行为障碍的二芳基脲和芳基脲衍生物
TW201720439A (zh) 2015-07-15 2017-06-16 Axovant Sciences Gmbh 用於預防及治療與神經退化性疾病相關的幻覺之作為５－ｈｔ２ａ血清素受體的二芳基及芳基雜芳基脲衍生物
US10399946B2 (en) 2015-09-10 2019-09-03 Laurel Therapeutics Ltd. Solid forms of an S-Nitrosoglutathione reductase inhibitor
WO2017050864A1 (en) 2015-09-23 2017-03-30 Janssen Pharmaceutica Nv New compounds
WO2017050865A1 (en) 2015-09-23 2017-03-30 Janssen Pharmaceutica Nv Bi-heteroaryl substituted 1,4-benzodiazepines and uses thereof for the treatment of cancer
KR20190062485A (ko) 2016-09-27 2019-06-05 버텍스 파마슈티칼스 인코포레이티드 Dna-손상제 및 dna-pk 저해제의 조합을 사용한 암 치료 방법
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
JP7568512B2 (ja) 2018-05-04 2024-10-16 インサイト・コーポレイション Ｆｇｆｒ阻害剤の塩
BR112020022392A2 (pt) 2018-05-04 2021-02-02 Incyte Corporation formas sólidas de um inibidor de fgfr e processos para preparação das mesmas
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
US12122767B2 (en) 2019-10-01 2024-10-22 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
JP7675711B2 (ja) 2019-10-14 2025-05-13 インサイト・コーポレイション Ｆｇｆｒ阻害剤としての二環式複素環
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
CA3163875A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
PE20221504A1 (es) 2019-12-04 2022-09-30 Incyte Corp Derivados de un inhibidor de fgfr
WO2021146424A1 (en) 2020-01-15 2021-07-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2022221170A1 (en) 2021-04-12 2022-10-20 Incyte Corporation Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
AR126102A1 (es) 2021-06-09 2023-09-13 Incyte Corp Heterociclos tricíclicos como inhibidores de fgfr
EP4352060A1 (en) 2021-06-09 2024-04-17 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1288436C (en) * 1983-07-22 1991-09-03 David Paul Hesson Phenylquinolinecarboxylic acids and derivatives as antitumor agents
US4888427A (en) * 1987-04-07 1989-12-19 University Of Florida Amino acids containing dihydropyridine ring systems for site-specific delivery of peptides to the brain
GB9004483D0 (en) * 1990-02-28 1990-04-25 Erba Carlo Spa New aryl-and heteroarylethenylene derivatives and process for their preparation
US5480883A (en) * 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
DK0584222T3 (da) * 1991-05-10 1998-02-23 Rhone Poulenc Rorer Int Bis-mono- og bicycliske aryl- og heteroarylforbindelser, som inhiberer EGF- og/eller PDGF-receptor-tyrosinkinase
US5710158A (en) 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US6177401B1 (en) * 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
NO306992B1 (no) * 1993-01-28 2000-01-24 Takeda Chemical Industries Ltd Quinolinderivater, farmasoeytiske preparater inneholdende forbindelsene og anvendelsen av forbindelsene
DE4426373A1 (de) * 1994-07-26 1996-02-01 Bayer Ag 3-Substituierte Chinolin-5-carbonsäurederivate und Verfahren zu ihrer Herstellung
WO1998003505A2 (en) * 1996-07-19 1998-01-29 Takeda Chemical Industries, Ltd. Heterocyclic compounds, their production and use
NZ336826A (en) * 1997-01-21 2000-06-23 Nissan Chemical Ind Ltd Industrial antimicrobial/mildew-proofing agents, algicides and antifouling agents containing N-quinoxalylanilines
KR100425638B1 (ko) * 1997-05-28 2004-04-03 아벤티스 파마슈티칼스 인크. 혈소판-유도된 성장 인자 및/또는 Ｐ５６ｌｃｋ 티로신키나제를 억제하는 퀴놀린 및 퀴녹살린 화합물

Also Published As

Publication number Publication date
IL133007A0 (en) 2001-03-19
HUP0002084A2 (hu) 2000-10-28
NO995817D0 (no) 1999-11-26
JP2002513417A (ja) 2002-05-08
PL337086A1 (en) 2000-07-31
EP1001946A4 (en) 2000-07-26
EA007807B1 (ru) 2007-02-27
ATE500233T1 (de) 2011-03-15
NO316377B1 (no) 2004-01-19
KR100440756B1 (ko) 2004-07-21
CZ415899A3 (cs) 2000-05-17
SK286084B6 (sk) 2008-03-05
PL194980B1 (pl) 2007-07-31
SK158199A3 (en) 2000-06-12
BG104006A (en) 2000-07-31
NO995819D0 (no) 1999-11-26
DE69828607D1 (de) 2005-02-17
WO1998054157A1 (en) 1998-12-03
AP1554A (en) 2006-01-18
EA199901090A1 (ru) 2000-08-28
IL133007A (en) 2005-06-19
PL195552B1 (pl) 2007-10-31
CZ418099A3 (cs) 2000-05-17
SK157999A3 (en) 2000-06-12
SI0991628T1 (en) 2005-06-30
WO1998054156A1 (en) 1998-12-03
AU742739B2 (en) 2002-01-10
BG103965A (en) 2000-07-31
CN1280572A (zh) 2001-01-17
HUP0004807A2 (hu) 2001-11-28
BG64419B1 (bg) 2005-01-31
EP0991628A1 (en) 2000-04-12
BR9809501A (pt) 2000-06-20
AP9901710A0 (en) 1999-12-31
CN1261354A (zh) 2000-07-26
ES2235331T3 (es) 2005-07-01
KR100425638B1 (ko) 2004-04-03
HK1028042A1 (en) 2001-02-02
AP1362A (en) 2005-01-19
BG64445B1 (en) 2005-02-28
EA008136B1 (ru) 2007-04-27
KR20010013057A (ko) 2001-02-26
NO995817L (no) 1999-11-26
CN1261353A (zh) 2000-07-26
EA200100575A1 (ru) 2002-02-28
JP2002500675A (ja) 2002-01-08
DE69828607T2 (de) 2006-01-05
NO995818D0 (no) 1999-11-26
NO995818L (no) 1999-11-26
CA2291728A1 (en) 1998-12-03
EA199901092A1 (ru) 2000-06-26
OA11264A (en) 2002-11-19
EP1001945A1 (en) 2000-05-24
EP0991628A4 (en) 2000-07-26
EA199901086A1 (ru) 2000-06-26
AU747026B2 (en) 2002-05-09
BR9809172A (pt) 2000-08-01
EP1001946B1 (en) 2010-12-29
HUP0004807A3 (en) 2001-12-28
AU7803798A (en) 1998-12-30
EP1001945B1 (en) 2011-03-02
SK158099A3 (en) 2000-06-12
WO1998054158A1 (en) 1998-12-03
NO323720B1 (no) 2007-06-25
BR9809515A (pt) 2000-06-20
CN1140516C (zh) 2004-03-03
DK0991628T3 (da) 2005-05-17
EA002600B1 (ru) 2002-06-27
CZ298490B6 (cs) 2007-10-17
CZ296845B6 (cs) 2006-07-12
IL133008A0 (en) 2001-03-19
NO323721B1 (no) 2007-06-25
KR20010039512A (ko) 2001-05-15
EP1001945A4 (en) 2000-07-26
AU7707998A (en) 1998-12-30
DE69842151D1 (de) 2011-04-14
HUP0002084A3 (en) 2000-12-28
JP2002500676A (ja) 2002-01-08
CZ417999A3 (cs) 2000-05-17
BG103963A (en) 2000-07-31
AU751188B2 (en) 2002-08-08
AP1444A (en) 2005-07-18
PL194670B1 (pl) 2007-06-29
AP9901709A0 (en) 1999-12-31
PL337084A1 (en) 2000-07-31
EP0991628B1 (en) 2005-01-12
AU751188C (en) 2005-06-30
DE69842077D1 (de) 2011-02-10
CZ298521B6 (cs) 2007-10-24
IL133009A0 (en) 2001-03-19
PT991628E (pt) 2005-05-31
CA2291774A1 (en) 1998-12-03
EP1001946A1 (en) 2000-05-24
OA11221A (en) 2003-07-16
ATE286886T1 (de) 2005-01-15
AP9901711A0 (en) 1999-12-31
ATE493389T1 (de) 2011-01-15
UA57790C2 (ru) 2003-07-15
EA004103B1 (ru) 2003-12-25
NO995819L (no) 1999-11-26
BG64444B1 (en) 2005-02-28
AU7706298A (en) 1998-12-30
PL337087A1 (en) 2000-07-31
CA2291750A1 (en) 1998-12-03

Similar Documents

Publication Publication Date Title
OA11222A (en) Quinoline and quinoxaline compounds which inhibit platelet-derived growt factor and/or p561 ck tyrosine kinases
US6180632B1 (en) Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
AU768625B2 (en) Quinoline and quinoxaline compounds as PDGF-R and/or LCK tyrosine kinase inhibitors
US6524347B1 (en) Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
KR100480360B1 (ko) 혈소판-유도된 성장 인자 및/또는 ｐ56ｌｃｋ 티로신 키나제를 억제하는 퀴놀린 및 퀴녹살린 화합물
MXPA99011017A (en) QUINOLINE AND QUINOXALINE COMPOUNDS WHICH INHIBIT PLATELET-DERIVED GROWTH FACTOR AND/OR p56lck
HUP0002219A2 (hu) Vérlemezke-eredetű növekedési faktor és/vagy p56lck tirozin kináz gátló hatású kinolin és kinoxalinszármazékok, valamint ezeket a vegyületeket tartalmazó gyógyászati készítmények